Weight loss drugs, already a relatively new and revolutionary concept within the medical industry, are shaking things up once again.
Move over Ozempic, pharmaceutical giant Eli Lilly has announced a new weight loss pill which, taken daily, is as successful in helping patients lose weight and maintain healthy blood sugar. It is already said to be as effective as the popular weekly injectables that have taken the United States by storm, allowing those who have struggled with weight loss to see quick results.
“I think we’re really at the beginning of a new era of preventing chronic disease,” said Eli Lilly & Company Chairman and CEO Dave Ricks in a segment on Fox Business.
“This is the first of seven studies that we’re doing to study this medicine, the oral GLP-1 inhibitor that we’ve been developing for more than eight years. And the results are exciting.”
The company released Phase 3 trial data on Thursday, indicating the pill requires no refrigeration, and no eating or drinking as it is taken. Early results show that it is as effective as Ozempic and helped recipients lose an average of 16 lbs.
Shares of Eli Lilly’s stock rose a shocking 16% following the announcement.
“[It’s a] big moment because people like orals better than injectables, typically. And we know there’s been supply constraints. Making the injectable medications is difficult, technically hard and expensive,” Ricks continued. “And this will be easier to make at scale. And so patients can be reassured there’ll be a constant supply.”
Trials will continue through 2025, and the medication is expected to be available for FDA review by the end of the year. It won’t hit market shelves until 2026.
“These medicines not only help people look better and feel better in the moment, but managing our weight over our lifetimes is one of the most important things we can do to prevent chronic diseases,” Ricks explained. “There’s more than 200 chronic diseases that can be improved if we control weight. And some of them are obvious, like heart attacks and strokes, which we think of, diabetes, [as] directly related to obesity. But some are less obvious like inflammation and joint pain, that we have studies on some of our other medicines. Lilly has 10 other GLP-1-like medicines.”
Writers and editors can be contacted at [email protected] with feedback, tips, or corrections.
Sierra Marlee is a millennial whose hunger for the truth in a world of fake news has led her to write. Marlee also contributes to BizPac Review.
- Trump was feeling frisky on social media this weekend, jaws hit the floor after what he posted on Hillary - May 19, 2025
- ‘He lied’: NYU grad has diploma suspended over anti-Israel political rant - May 17, 2025
- ‘Missed you today’: Ivanka leaves note for admiring Eagles player after locker room visit - May 17, 2025
Comment
We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.